0000358654
Donate

Reimbursement status:
Full reimbursement

Cancer: Lymphocytic leukaemia

Indication:

Chronic lymphocytic leukaemia (CLL): rituximab in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory CLL. Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including rituximab or patients refractory to previous rituximab plus chemotherapy.

Reimbursement information:

EPAR/SmPC

Drug programme

Details

ATC category :
L01XC
L01XC Monoclonal antibodies
EMA approval status :
Approved
EMA approval date :
2009-02-23
EMA conditional? :
No
EMA orphan? :
No
EMA biological? :
Yes